Short Interest Watching: Is Buying AMARANTUS BIOSCIENCE HOLDINGS IN (OTCMKTS:AMBS) Here Good Idea?

November 24, 2016 - By Nellie Frank   ·   0 Comments

Short Interest Watching: Is Buying AMARANTUS BIOSCIENCE HOLDINGS IN (OTCMKTS:AMBS) Here Good Idea?

The stock of AMARANTUS BIOSCIENCE HOLDINGS IN (OTCMKTS:AMBS) registered a decrease of 79.87% in short interest. AMBS’s total short interest was 22,500 shares in November as published by FINRA. Its down 79.87% from 111,800 shares, reported previously. The stock decreased 1.64% or $0.0005 on November 23, hitting $0.03. About 258,163 shares traded hands. Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) has declined 50.00% since April 22, 2016 and is downtrending. It has underperformed by 55.41% the S&P500.

Amarantus Bioscience Holdings, Inc. is a biopharmaceutical holding company. The company has a market cap of $1.96 million. The Firm has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. It currently has negative earnings. It owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry.

AMBS Company Profile

Amarantus Bioscience Holdings, Inc., incorporated on March 22, 2013, is a biopharmaceutical holding company. The Firm has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. It owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry. The Firm is developing diagnostic product candidates in the field of neurology, and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Firm owns intellectual property rights to approximately two diagnostic blood test platforms: NuroPro and BC-. NuroPro is a neurodegenerative disease diagnostic platform with an application in Parkinson’s disease. BC-SeraPro is an oncology diagnostic platform with an application in breast cancer.

More notable recent Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) news were published by: Prnewswire.com which released: “Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience …” on November 19, 2014, also Globenewswire.com with their article: “Amarantus Effects Capital Restructuring in Anticipation of National Exchange …” published on May 22, 2015, Globenewswire.com published: “Amarantus Closes $5 Million Preferred Stock Financing” on April 27, 2015. More interesting news about Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) were released by: Globenewswire.com and their article: “Amarantus Completes Capital Restructuring in Preparation for National Exchange …” published on June 09, 2015 as well as Seekingalpha.com‘s news article titled: “Amarantus BioScience’s (AMBS) CEO Gerald Commissiong Hosts Business Update …” with publication date: May 28, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Nellie Frank


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>